GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mallinckrodt PLC (OTCPK:MCKPF) » Definitions » Cyclically Adjusted PS Ratio

Mallinckrodt (Mallinckrodt) Cyclically Adjusted PS Ratio : 0.00 (As of Jun. 08, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Mallinckrodt Cyclically Adjusted PS Ratio?

As of today (2024-06-08), Mallinckrodt's current share price is $0.12. Mallinckrodt's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $52.12. Mallinckrodt's Cyclically Adjusted PS Ratio for today is 0.00.

The historical rank and industry rank for Mallinckrodt's Cyclically Adjusted PS Ratio or its related term are showing as below:

During the past years, Mallinckrodt's highest Cyclically Adjusted PS Ratio was 0.78. The lowest was 0.01. And the median was 0.20.

MCKPF's Cyclically Adjusted PS Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.05
* Ranked among companies with meaningful Cyclically Adjusted PS Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Mallinckrodt's adjusted revenue per share data for the three months ended in Mar. 2024 was $23.746. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $52.12 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Mallinckrodt Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Mallinckrodt's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mallinckrodt Cyclically Adjusted PS Ratio Chart

Mallinckrodt Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.19

Mallinckrodt Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.17 0.03 - -

Competitive Comparison of Mallinckrodt's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Mallinckrodt's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mallinckrodt's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mallinckrodt's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Mallinckrodt's Cyclically Adjusted PS Ratio falls into.



Mallinckrodt Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Mallinckrodt's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.12/52.12
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mallinckrodt's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Mallinckrodt's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=23.746/120.9901*120.9901
=23.746

Current CPI (Mar. 2024) = 120.9901.

Mallinckrodt Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 9.438 100.573 11.354
201406 11.164 100.773 13.404
201409 -1.186 100.474 -1.428
201412 6.605 99.576 8.025
201503 6.988 99.975 8.457
201506 7.447 100.573 8.959
201509 3.911 100.274 4.719
201512 6.975 99.676 8.466
201603 8.196 99.676 9.949
201606 8.872 101.072 10.620
201609 5.336 100.274 6.438
201612 7.851 99.676 9.530
201703 7.827 100.374 9.435
201706 8.354 100.673 10.040
201709 6.192 100.474 7.456
201712 15.828 100.075 19.136
201803 8.772 100.573 10.553
201806 9.886 101.072 11.834
201809 9.411 101.371 11.232
201812 10.011 100.773 12.019
201903 9.345 101.670 11.121
201906 9.825 102.168 11.635
201909 8.854 102.268 10.475
201912 9.559 102.068 11.331
202003 7.907 102.367 9.345
202006 1.970 101.769 2.342
202009 8.254 101.072 9.881
202012 8.052 101.072 9.639
202103 6.596 102.367 7.796
202106 6.451 103.364 7.551
202109 5.988 104.859 6.909
202112 7.051 106.653 7.999
202203 5.796 109.245 6.419
202206 4.525 112.779 4.854
202209 41.697 113.504 44.447
202212 37.068 115.436 38.852
202303 32.167 117.609 33.092
202306 35.985 119.662 36.384
202309 37.090 120.749 37.164
202403 23.746 120.990 23.746

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Mallinckrodt  (OTCPK:MCKPF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Mallinckrodt Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Mallinckrodt's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Mallinckrodt (Mallinckrodt) Business Description

Traded in Other Exchanges
N/A
Address
College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, IRL, 15
Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which include specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of its revenue from the United States.
Executives
Alta Fundamental Advisers Llc 10 percent owner 1500 BROADWAY, SUITE 704, NEW YORK NY 10036
Jason Daniel Goodson officer: EVP & Head of Corp Development 106 CENTRAL PARK AVENUE, WENTZVILLE MO 63885
James R Sulat director
Paul Bisaro director
Sigurdur O Olafsson director, officer: President and CEO 360 MOUNT KEMBLE AVENUE, MORRISTOWN NJ 07960
Stephen Andrew Welch officer: EVP & Head of Spec Generics 18440 BRIDGEMORE LANE, LOUISVILLE KY 40245
Peter C Richardson officer: EVP & Chief Scientific Officer 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Susan Michele Silbermann director C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Lisa French officer: EVP & Chief Commercial Officer 301 CONTINENTAL LANE, PAOLI PA 19301
Mark Anthony Tyndall officer: EVP & Chief Legal Offi & Secre 1101 Q ST NW, WASHINGTON DC 20009
Henriette Nielsen officer: EVP & Chief Transformation OFC 202 WEST 85TH STREET, APT. 5, NEW YORK NY 10024
Karen Ling director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Anne Clem Whitaker director 109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
Olifant Luxco S.a R.l. 10 percent owner 19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273
Paul Rutherford Carter director SOUTH BUILDING, 2 ROUNDWOOD AVENUE, STOCKLEY PARK X0 UB11 1AF

Mallinckrodt (Mallinckrodt) Headlines

From GuruFocus